

PATENT
674523-2028

30. (Previously amended) The retroviral vector particle according to claim 29, wherein the oncoretrovirus is a murine leukemia virus (MLV).

31. (Currently amended) The retroviral vector particle according to claim 24, wherein the retroviral polynucleotide response element comprises all or a portion of a lentiviral lentiviral response element.

32. (Previously amended) The retroviral vector particle according to claim 31, wherein the lentivirus is an HIV virus.

33. (Previously amended) The retroviral vector particle according to claim 24, wherein a packaging signal is contained within the intron in which the NS is located.

34. (Currently amended) A DNA construct encoding a packageable RNA genome for a retroviral vector particle, wherein the retroviral vector particle, when in the form of a DNA provirus, comprises:

(i) a 5'LTR comprising an HIV U3 and R region, or functional portions thereof having Tat inducible promoter activity;

(ii) at least one nucleotide sequence (NS) capable of being expressed in a target cell; and

(iii) at least one retroviral polynucleotide response element (PRE) which is responsive to a nucleus to cytoplasm transport factor;

wherein the NS and the PRE are located within an intron in a transcription unit of the provirus, wherein the intron is defined by flanking retroviral splice donor (SD) and retroviral splice acceptor (SA) sites derived from different retroviruses,

wherein said NS is capable of expression in Tat and Rev expressing cells, and NS expression is undetectable in cells not expressing Tat and Rev genes; and

wherein the construct is operably linked to a promoter.

35. (Cancelled)

36. (Previously amended) The DNA construct according to claim 34, wherein the NS is absent and the construct comprises an insertion site within the intron containing the PRE at which one or more NS may be inserted.

37. (Currently amended) A DNA construct encoding a packageable RNA genome for a retroviral vector particle, wherein the retroviral vector particle, when in the form of a DNA provirus, comprises:

PATENT
674523-2028

- (i) a 5'LTR comprising an HIV U3 and R region, ~~or functional portions thereof~~ having Tat inducible promoter activity; and
 - (ii) at least one retroviral polynucleotide response element (PRE) which is responsive to a nucleus to cytoplasm transport factor;
- wherein the PRE is located within an intron in a transcription unit of the provirus,
wherein the intron is flanked by a retroviral splice donoe (SD) site and a retroviral splice acceptor (SA) site derived from different retroviruses,
wherein the construct comprises an insertion site within the intron containing the PRE at which one or more nucleotide sequences (NS) may be inserted; and
wherein the construct is operably linked to a promoter.
38. (Previously added) A retroviral vector particle production system comprising a host cell transfected with the DNA construct according to claim 34.
39. (Cancelled)
40. (Previously amended) An *in vitro* method for infecting or transducing a target cell with a retroviral vector, the method comprising:
- (i) contacting the target cell with the retroviral vector according to claim 24;
- and
- (ii) selecting for a target cell that expresses the NS.
41. (Previously amended) Target cells produced by the method of claim 40.
42. (Previously added) The retroviral vector particle of claim 24, wherein the SA site is derived from HIV.
43. (Previously added) The retroviral vector particle of claim 24, wherein the SD site is derived from MLV.